The Effect of Tetrahydrocannabinol on Ocular Hemodynamics in Healthy Subjects

Inclusion criteria

• Men and women aged between 18 and 35 years
• Normal ophthalmic findings
• Ametropia ≤ 6 diopters
• Normal findings in the medical history and physical examination including ECG unless the investigator considers an abnormality to be clinically irrelevant
• Normal findings in the laboratory testing unless the investigator considers an abnormality to be clinically irrelevant
• Nonsmokers

Exclusion criteria

• Regular use of medication, abuse of alcoholic beverages or drugs
• History of drug or alcohol abuse
• Psychiatric disorders in the medical history
• Risk for drug dependence as evaluated by a psychiatrist
• Participation in a clinical trial in the 3 weeks preceding the study
• Positive urine drug test at the screening examination or on the study days
• Positive alcohol breath test at the screening examination or on the study days
• Regular consumption of cannabis and inability to not consume cannabis during the study period
• Treatment in the previous 3 weeks with any drug (except intake of oral contraceptives)
• Symptoms of a clinically relevant illness in the 3 weeks before the first study day
• History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of study drugs
• Blood donation during the previous 3 weeks
• Known hypersensitivity to any of the components of the IMP under investigation or other study medication
• History or family history of epilepsy
• Pregnant or breast-feeding women
• Women of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception (oral contraceptives, intra-uterine device, contraceptive implant or condoms)